|
Jul 7
|
High Growth Tech Stocks To Watch In The US July 2025
|
|
Jul 6
|
BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA
|
|
Jul 2
|
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights
|
|
Jun 30
|
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
|
|
Jun 26
|
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
|
|
Jun 25
|
TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
|
|
Jun 24
|
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
|
|
Jun 20
|
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with ‘Outperform’ Rating
|
|
Jun 11
|
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
|
|
Feb 13
|
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
|
|
Feb 13
|
BridgeBio price target raised to $49 from $48 at Scotiabank
|
|
Feb 12
|
EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment
|
|
Feb 11
|
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
|
|
Feb 11
|
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
|
|
Feb 8
|
Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts
|
|
Jan 15
|
Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers?
|
|
Jan 14
|
BridgeBio Pharma Stock Earns 87 RS Rating
|
|
Jan 14
|
Why BridgeBio Pharma (BBIO) Led the Monday Upsurge?
|
|
Oct 4
|
3 Top Stocks That Could Still Rocket Higher in 2024
|
|
Oct 3
|
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
|